Kornimate/medical-research-clean huggingface dataset:
the effect of gluten-free diet in type 1 diabetics with dyspepsia symptoms

Conditions: Diabetes Mellitus, Type 1; Gastroparesis; Dyspepsia; Gluten Sensitivity

Summary: patients with type-1 diabetes are more susceptible to motility-related upper gastrointestinal symptoms. dietary interventions are one of the treatment pillars for these symptoms. many gastrointestinal conditions other than celiac disease, are being increasingly treated with gluten-free diet (gfd). the role of gfd in non-celiac type-1 diabetic patients with dyspepsia-like symptoms has not been assessed before. in this study, type 1 diabetes patients with concomitant upper gastrointestinal symptoms will be asked to follow a 1-month gfd to assess changes in upper gastrointestinal symptoms and gastroduodenal motility before and after the dietary intervention.

diabetes mellitus (dm) is a complex and heterogeneous disease that is associated with poor outcomes. in studies from referral centers, 50-65% of diabetics reported dyspeptic symptoms. in addition, approximately 50% of type 1 dm (t1dm) patients, especially those with longstanding disease, have evidence of delayed gastric emptying. dietary modification is one of the treatment pillars for patients with dyspeptic symptoms. further, many individuals in which both symptoms and motility abnormalities improve after a gfd have positive anti-gliadin antibodies (aga), which reinforces the role of gluten-induced inflammation/immune activation as a possible cause of motility abnormalities and related symptoms. ameliorating ugi symptoms is not only pivotal for improving the quality of life of diabetic gp patients, but the improvement in gastroduodenal motility is also needed for a more predictable glycemic response. in non-celiac t1dm patients, the role of the gfd in symptom improvement, gastroduodenal motility and glycemic control has never been assessed. the overall aim of the present study is to improve the knowledge about the role of dietary interventions as non-pharmacological treatments for upper-gastrointestinal symptoms and underlying motility abnormalities in patients with type 1 diabetes. this will be a non-randomized, open label, before and after trial of a 1-month gfd in non-celiac type 1 diabetics to assess symptomatic, motility and glycemic response changes.

Eligibility criteria:
inclusion criteria: * adult men and women (18-75 years) with type 1 diabetes diagnosis and no history of celiac disease, that complain of upper gastrointestinal symptoms (early satiety, postprandial fullness, bloating, abdominal swelling, nausea, vomiting, and retching) will be invited to participate. exclusion criteria: * patients with very severe symptoms of gastroparesis that require specialized nutritional therapy or surgical treatment; * pregnant women; * patients with concomitant diseases/treatments that can alter gastrointestinal motility and concomitant severe systemic diseases.

Keywords: gluten-free diet gluten sensitivity dyspepsia diabetes mellitus, type 1 gastroparesis motility
sunnyday: subepithelialgastrointestinal tumors detection,accuracydiagnosis,elastography and contrast-enhanced eus

Conditions: Subepithelial Gastrointestinal Tumors

Summary: this will be a longitudinal, prospective, observational multicenter study where the role of eus-e will be examined in differentiating subepithelial gastrointestinal tumors in 138 patients

this will be a longitudinal, prospective, observational multicenter study that will enroll consecutive patients, with gastrointestinal sets diagnosed by experienced endoscopists at italian hospitals. this study will be conducted following the helsinki declaration after the approval by the ethics review board of all centers and will be recorded on clinical-trials.gov. all patients will provide their written informed consent for participating in the study. the eus-e and ceus analysis with sonovue® will be performed during the same procedures. a subsequent diagnostic hypothesis on the nature of sets will be formulated based on the b-mode, eus-e, and ce-eus characteristics.

Eligibility criteria:
inclusion criteria: 1. patients with gi sets scheduled for eus-fnb 2 patients with age \> 18 but \<85 exclusion criteria: 1. patients with gi sets \<15mm 2. severe coagulopathy defined as abnormal prothrombin time (pt) or partial thromboplastin time (ptt) that does not normalize after administration of fresh frozen plasma 3. severe cardiopulmonary diseases and severe chronic kidney disease defined as 4. known allergic disposition to sonovue® 5. pregnancy

Keywords: subepithelial gastrointestinal tumors endoscopic ultrasound eus sets eus elastography surgical resection histopatological specimens
group cognitive behavior sessions (cbcsm) to decrease distress in cancer patients

Conditions: Hematopoietic and Lymphoid System Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm

Summary: this clinical trial tests how well cognitive behavioral cancer stress management (cbcsm) group sessions work to decrease psychological distress in cancer patients. cbcsm teaches patients how to recognize and reduce the impacts of cancer associated stress on the biological, psychological, and social life domains.

primary objective: i. to reduce psychological stress. secondary objectives: i. to increase post-traumatic growth (ptg). ii. to increase patient self-efficacy in utilizing therapy skills. iii. to estimate patient acceptability and feasibility of conducting cbcsm within the clinical setting. iv. to estimate differences of conducting cbcsm virtually during the public health emergency (phe) versus in person pre-phe. v. to estimate differences of conducting cbcsm post phe virtually with limitation to minnesota patients only. vi. to explore the difference using the same therapy in patients with advanced, metastatic disease in a individual setting versus patients without the advanced, metastatic disease in a group setting. outline: patients are assigned to 1 of 2 groups. group i: patients participate in five cbcsm group sessions on study. patients complete questionnaires throughout the trial and during follow-up at 1, 3, 6, and 12 months. group ii: patients complete questionnaires throughout the trial and during follow-up at 1, 3, 6, and 12 months.

Eligibility criteria:
inclusion criteria: * eligible for the cognitive behavioral cancer stress management (cbcsm) clinical service * cancer diagnosis with predicted survival \> 1 year * cancer treatment within past 1 year or treatment planning in progress * age \>= 18-years * moderate distress screen, indicated by impact of event scale-revised (ies-r) score \>= 14 or clinical judgment * written informed research consent exclusion criteria: * inability to actively participate in and learn from group therapy (e.g., psychotic symptoms, neurological condition, personality pathology) as determined by clinical judgment in clinical consultation (individual therapy or alternative group therapy will be offered)
universal car-t cells in patients with refractory autoimmune diseases of the nervous system.

Conditions: Neuromyelitis Optica Spectrum Disorders; Myasthenia Gravis, Generalized; Multiple Sclerosis; Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Summary: this is an open label, single-site, dose-escalation study in up to 25 participants with refractory autoimmune diseases of nervous system. this study aims to evaluate the safety and efficacy of the treatment with universal bcma and cd19 cart.


Eligibility criteria:
inclusion criteria: * aged 18-75 years (for ms patients, 18-55 years); both genders eligible. * subjects with refractory neurological autoimmune diseases who have failed standard treatment or lack effective treatment, including neuromyelitis optica spectrum disorders(nmosd), generalized myasthenia gravis(gmg), chronic inflammatory demyelinating polyradiculoneuropathy(cidp) and multiple sclerosis(ms). * anticipated survival of ≥ 12 weeks as judged by the researcher. * agrees to use double barrier methods, condoms, oral or injectable contraceptives, or intrauterine devices during the study period and for one year after taking the study medication. * provides written informed consent. exclusion criteria: * history of solid organ transplantation. * malignant tumor within the last two years. * positive for hepatitis b surface antigen (hbsag) or hepatitis b core antibody (hbcab), with peripheral blood hepatitis b virus (hbv) dna detected as positive; positive for hepatitis c virus antibodies, with peripheral blood hepatitis c virus rna detected as positive; positive for human immunodeficiency virus (hiv) antibodies; positive for cytomegalovirus (cmv) dna; positive for syphilis. * primary immunodeficiency (congenital or acquired). * severe cardiac disease. * history of psychiatric disorders or history of psychotropic drug abuse, with no history of withdrawal. * allergic constitution or a history of severe allergies. * pregnant or breastfeeding women.

Keywords: universal car-t neuromyelitis optica spectrum disorders myasthenia gravis multiple sclerosis chronic inflammatory demyelinating polyradiculoneuropathy
a study to investigate the efficacy, safety, and tolerability of jnj-42165279 in adolescent and adult participants with autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: the purpose of this study is to evaluate the efficacy of jnj-42165279 compared with placebo in the improvement of symptoms of autism spectrum disorder (asd) during 12 weeks of treatment using the autism behavior inventory (abi).


Eligibility criteria:
inclusion criteria: * diagnosis of autism spectrum disorder (asd) according to diagnostic and statistical manual of mental disorders - 5th edition (dsm-5) criteria and made or confirmed using the autism diagnostic observation schedule, 2nd edition (ados-2) (minimum score of 8 \[autism spectrum\]) * otherwise healthy for their age group or medically stable with or without medication on the basis of physical examination, medical history, vital signs, 12-lead electrocardiogram (ecg), and clinical laboratory tests * have a composite score on kaufman brief intelligence test, second edition (kbit-2) of at least 60 * must live with a parent or primary caregiver or, if not, during each week he/she must either (a) spend at least 3 hours a day for at least 4 days or, (b) spend the weekend with a parent or primary caregiver * any pharmacologic, diet, or behavioral intervention for asd must have begun at least 1 month prior to the baseline visit and continue unchanged through the treatment period, or have ended at least 1 month prior to the baseline visit * must be able to swallow the study medication whole and self-administer medication if living independently or have a parent or caregiver be able to administer medication * must agree to abide by the birth control requirements during the study and for 3 months after the last dose exclusion criteria: * current or recent history of clinically significant suicidal ideation within the past 6 months, or a history of suicidal behavior within the past year * use of a drug with moderate/strong cytochrome p450 (cyp)3a4 inhibiting or inducing properties at, or prior to, screening that is not discontinued at least within 1 month prior to day 1 * history of drug or alcohol use disorder according to dsm-5 criteria within 6 months before screening or positive test result(s) for alcohol or drugs of abuse (except if related to current treatment) * currently taking or has taken within the past month recreational or medically prescribed cannabis
a study to evaluate different intervals between dosing and feeding on the pharmacokinetics

Conditions: Immune Thrombocytopenia

Summary: this study use a single-center, randomized, open, three-cycle, self-control trial design. it is planning to enroll 15 healthy adult male subjects. fifteen subjects will randomize into 3 test groups which corresponding to 3 different dosing sequences. subjects will be giving a single oral dose in per cycle, and there will have three types of breakfast administration after each treatment. washing period is 10 days during the cycle.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. the subject's body weight was ≥ 50.0 kg, bmi was between 19 and 26 kg/m2 3. signed informed consent. exclusion criteria: 1. any clinically serious disease that has or is currently suffering from circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric, and metabolic abnormalities, or any other disease that can interfere with the test results 2. having deep vein thrombosis or other thrombotic diseases. 3. having thrombocytopenia, mitral valve prolapse, obvious heart murmur, or murmur. 4. extended qt interval during the screening period (calculated in bazett's method, males \>450 msec) 5. hepatitis b surface antigen, hepatitis c antibody, syphilis antibody, hiv antibody positive. 6. those who have a history of allergies to drugs , food or test drugs or similar drugs; 7. those who have undergone surgery within 4 weeks prior to the trial or plan to perform surgery during the study 8. those who took any drug within 14 days before the test (including chinese herbal medicine) 9. any drug that inhibits or induces liver drug metabolism within 30 days before the test 10. subjects have participated in other clinical trial within the 3 months prior to study entry. 11. one or more non-pharmacological contraceptive measures cannot be used during the trial, or it is planned to have birth within six months.
comparative effectiveness of acupuncture and nonsteroidal anti-inflammatory drugs for the management of aromatase inhibitor induced arthralgia among breast cancer survivors

Conditions: Breast Cancer

Summary: hormone therapy is used to treat women with hormone receptor-positive breast cancer and aromatase inhibitor (ai) is administered after menopause. ai therapy has been proven to be effective in improving the disease-free survival rate, decreasing the recurrence rates and a lower incidence of contralateral breast cancer. however, arthralgia frequently reported as an important adverse event of ai therapy and sometimes resulted in noncompliance with ai therapy. the prevalence of ai induced arthralgia rates ranged from 20 to 74%. inadequately managed ai induced arthralgia remains a major unmet need in oncology practice in breast cancer survivors. the goal of this project is to conduct a crossover designed pragmatic clinical trial to evaluate the effectiveness of acupuncture versus nsaid (diclofenac) for the management of aromatase inhibitor induced arthralgia. the third group was set to use non-steroidal analgesics plus acupuncture to evaluate the effectiveness of joint pain.


Eligibility criteria:
inclusion criteria: * women who were postmenopausal aged more than 20 years old. * history of stage 0 to iii hormone receptor-positive breast cancer, and currently taking a third-generation ai (anastrozole, letrozole, or exemestane) for at least 3 month. * those who reported pain and/or stiffness in one or more joints, which started or worsened after initiation of ai therapy had worst joint pain rated at least three or greater on a 0-10 numerical rating scale in the preceding week. exclusion criteria: * any prior acupuncture use for ai-induced joint symptoms or acupuncture within 1 months before entry * inflammatory, metabolic, or neuropathic arthropathies * bone fracture/surgery of an afflicted extremity during the preceding 6 months * allergy to nsaid * current use of narcotics * bleeding or coagulation disorders * localized skin infections * needle phobia * intra-articular corticosteroid within 4 weeks preceding the study * any severe chronic or uncontrolled comorbid disease

Keywords: acupuncture
supplementary effects of resistance training in addition to joint mobilization in persons with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: joint mobilization and resistance exercise training are effective conservative treatment options for the management of osteoarthritis. however, currently no study has highlighted the supplementary effects of resistance training in addition to joint mobilization in people suffering from knee osteoarthritis. the current study is aimed at bridging the gap in literature and providing evidence regarding the additive impact of resistance training to joint mobilization in knee osteoarthritis.


Eligibility criteria:
inclusion criteria: * knee oa grade i-iii * individuals of either gender aged 40-70 years * knee oa history of no less than 3 months * knee pain no more than 8/10 cm on the visual analogue scale (vas) * radiological evidence of grade iii or less on kellgren classification. exclusion criteria: * those with signs of serious pathology such as malignancy, inflammatory disorder or infection. * history of trauma or fractures in lower extremity * signs of lumbar radiculopathy or myelopathy * history of knee surgery or replacement and/or receiving intra-articular steroid therapy in the preceding two months
the incidence of perioperative deep venous thromboses of the lower extremities

Conditions: Perioperative DVTs

Summary: the study's hypothesis is that there are some patients who come for surgery who have asymptomatic clots in their lower extremities upon their arrival to the hospital for their surgical admission. we will be performing duplex studies of the subjects' legs before their surgery to determine how often clots are present. we will also perform duplex scans of the legs after the subjects' surgeries to determine what factors (surgical, anesthetic, co-morbidities)are correlated with the development of dvts.


Eligibility criteria:
inclusion criteria: * age 18+ and consentable exclusion criteria: * anticoagulation therapy or known dvt

Keywords: surgery deep vein thrombosis preoperative
deep brain stimulation follow-up after 10 years

Conditions: Parkinson's Disease

Summary: the purpose of this study is to examine the long-term effect of deep brain stimulation (dbs) for patients with parkinson's disease. we have data for patients operated with dbs since 1998. we wish to examine the effect of stimulation on motor symptoms as well as make a follow-up on complications and side-effects related to treatment. we also wish to follow-up on the quality of life-studies made in the years 2003-2008.

parkinson's disease (pd) is caused by a progressive loss of dopamine-producing cells in substantia nigra in mesencephalon. pd is characterized by the symptoms resting tremor, rigidity and bradykinesia. later in the course of the disease, patients develop gait- and balance symptoms. in the first years of the disease, the patients' symptoms are treated well with levodopa. as the disease develops and the loss of dopamine-producing cells grows, the physiological buffer-capacity for levodopa is lost and patients develop motor fluctuations in the shape of on-off symptoms and dyskinesias. patients with these symptoms may benefit from implantation of electrodes in the subthalamic nucleus, which is stimulated by an pulse generator on the chest. a number of studies have found a long-term effect of dbs, but most of these studies have a follow-up time of no more than five years. overall, these studies show a beneficial effect of dbs after five years: the patients need less medication, the number of off-periods is decreased and they score lower on the unified parkinson disease rating scale, part three. however, the axial symptoms and the bradykinesia progress. as of yet, few studies examine the effect of deep brain stimulation after 10 years. in our study we wish to examine the effect of dbs for all patients operated at aarhus university hospital in the years 1998-2002, which gives us a follow-up time of 10-14 years.

Eligibility criteria:
inclusion criteria: * patients with parkinson's disease treated with dbs at aarhus university hospital in the years 1998-2002. exclusion criteria: * dementia, i.e. mmse\<24 * dbs removed * deceased

Keywords: parkinson's disease stimulation, deep brain study, follow-up adverse effects
motion perception in individuals with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: is the ability to perceive motion altered by diabetes? the investigators are measuring motion perception using a technique called vestibular thresholds. subjects will undergo 3 hours of testing in which they sit in a chair that makes small movements and report their perception of motion. the investigators are currently looking for individuals who have had type 2 diabetes for at least 10 years.

previous studies have found that individuals with diabetes fall more frequently, have less stable posture, and have reduced motion and touch sensation in the lower extremities. this study will examine whether vestibular sensation is also affected by diabetes. this study is observational because measurements will be made without the application of an intervention. the same measurement protocol was applied to a large group of normal subjects, and this published data will serve as normative controls.

Eligibility criteria:
inclusion criteria: * type 2 diabetes for at least 10 years * under 250 pounds exclusion criteria: * medications not to be used include: ambien (zolpidem), antivert, bonine (meclizine), ativan (lorazepam), benadryl (diphenhydramine), dalmane (flurazepam), dramamine, doral (quazepam), fiorinal, fiorcet (butalbital), halcion (triazolam), klonopin (clonazepam), librium, librax (chlordiazepoxide), nembutal (pentobarbital), phenergan (promethazine), placidyl (ethchlorvynol), prosom (estazolam), restoril (temazepam), seconal (secobarbital), serax (oxazepam), transderm scopes patch, vontrol (diphenidol), xanax (alprazolam). * individuals meeting the following criteria will be excluded: a) a history of head trauma, b) posterior fossa pathology, c) a well-defined otologic diagnosis (e.g., benign paroxysmal positional vertigo (bppv), meniere's disease, superior canal dehiscence, etc., unilateral or bilateral vestibular hypofunction) d) a recent history of seizures e) any other major neurologic (e.g., parkinson's, multiple sclerosis, dementia, epilepsy, cerebellar ataxia, stroke, recent concussion, etc.) disorder, f) any major psychiatric (e.g., panic disorder, psychosis, etc.) disorder, and g) any other severe health problem (heart disease, pulmonary disease, cancer, etc.). * due to nauseogenic nature of some motions and to protect fetus and mother, pregnant women will also be excluded from this study.